Breaking News


Psoriasis activity following adalimumab discontinuation and its effectiveness on retreatment


Psoriasis patients who had responded with a Psoriasis Area and Severity Index (PASI) score of a 75 or greater decrease from baseline at weeks 16 and 33 in a double-blind, randomized, placebo-controlled trial of adalimumab were re-randomized at weeks 33-52. They were re-randomized to either adalimumab (n = 250) or placebo (n = 240). Patients who completed this phase or lost adequate response could then receive an open-label extension (OLE) on adalimumab for 24 weeks. Post hoc analysis of the 227 patients who received placebo in the re-randomization phase determined their PASI responses at OLE week 24 (relative to baseline) for patients grouped by PASI response at week 0, in addition ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list